Scientists confirmed that tiotropium bromide treats patients with early chronic obstructive pulmonary disease

Recently, a large-scale clinical study on the treatment of early chronic obstructive Pulmonary Disease (Tie-COPD) led by the Guangzhou Institute of Respiratory Diseases, the National Clinical Research Center for Respiratory Diseases, and the State Key Laboratory of Respiratory Diseases of the Affiliated Hospital of Guangzhou Medical University (led by the Guangzhou Institute of Respiratory Diseases, the National Clinical Research Center for Respiratory Diseases, and the State Key Laboratory of Respiratory Diseases, with the participation of a number of domestic hospitals, has made breakthroughs in the treatment of early chronic obstructive pulmonary disease (Tie-COPD), confirming that the use of tiotropium bromide to treat patients with early chronic obstructive pulmonary disease is safe and effective.The results of the study were published in the New England Journal of Medicine.

Chronic obstructive pulmonary disease is currently one of the diseases with high morbidity and mortality rates in the world.In China, chronic obstructive pulmonary disease has become one of the three deadly health killers, and the prevalence of chronic obstructive pulmonary disease in people over the age of 40 in our country reaches 8.2%.In earlier studies, the team found that more than 70% of patients with chronic obstructive pulmonary disease were early-stage patients, but most of them did not actively seek medical help because they were asymptomatic or had mild symptoms. In the late stage, the treatment effect was poor, and the mortality rate, readmission rate and disability rate were all very high.At the same time, patients with chronic obstructive pulmonary disease have a more rapid decline in early lung function.Therefore, it is very important to find an effective way to intervene in patients with early chronic obstructive pulmonary disease.